Seres Therapeutics

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seres Therapeutics poised for FDA approval with strong pipeline progress

Seres Therapeutics is well-positioned for potential FDA approval of SER-109, backed by strong Phase III efficacy and safety data. The company's financial stability and strategic collaborations underscore a focused approach towards commercial success. Addressing key challenges and leveraging opportunities in product development and market entry will be crucial for Seres Therapeutics' future growth.

Seres Therapeutics secures FDA approval for VOWST, eyes commercial success

Seres Therapeutics is poised for success with FDA approval of VOWST and positive study results for SER-155. The company faces challenges in ensuring consistent engraftment and optimizing operational efficiencies. Opportunities lie in commercializing VOWST and advancing microbiome therapeutics.

Seres Therapeutics reports robust Q2 earnings, eyes VOWST growth

Seres Therapeutics had a strong Q2 2023, propelled by VOWST approval and positive sales performance, positioning the company for continued growth.
While facing challenges like Medicare affordability issues and net losses, Seres remains optimistic about VOWST's potential and profitability trajectory.
By capitalizing on opportunities in education, expansion, and efficiency, Seres aims to drive VOWST adoption, enhance market presence, and achieve financial success.

Seres Therapeutics excels in Q3 with VOWST launch success

Seres Therapeutics reported a strong Q3 performance with the successful VOWST launch, despite a net loss. The company's restructuring focuses on VOWST's growth and long-term sustainability. Challenges include optimizing VOWST sales and navigating reimbursement differences.

Seres Therapeutics excels in 2023 with VOWST launch and financial focus

Seres Therapeutics had a strong 2023, marked by successful product launches, financial discipline, and promising development in microbiome therapeutics.
The company's strengths include innovation, financial stability, strong leadership, and efficient budget management, positioning them for future growth.
Challenges include sustaining momentum, securing funding for advancement, meeting regulatory expectations, and ensuring positive patient experiences.
Opportunities lie in continued growth, partnerships, strategic funding, innovation, and establishing a compelling market narrative.
Overall, Seres Therapeutics is well-positioned for success in the microbiome therapeutics market, with a focus on product development and financial discipline.

Seres Therapeutics reports robust Q1 sales and advances pipeline growth

Seres Therapeutics demonstrated strong sales performance with VOWST net sales reaching $10.1 million in Q1 2024.
The company's focus on commercialization of VOWST and advancement of microbiome therapeutic candidates like SER-155 shows promise for future growth.
Challenges in pricing, inventory management, and funding are being addressed, while opportunities in new patient populations and strategic partnerships are being explored.

Seres Therapeutics sells VOWST assets, reports strong Q2 earnings

Seres Therapeutics' Q2 performance was marked by a strategic asset sale, strong financial results, and progress in key pipeline programs. The company's focus on transformative therapies and data-driven pipeline prioritization positions it well for future growth and impact in the healthcare sector.

Seres Therapeutics reports Q3 loss but sees growth opportunities ahead

Seres Therapeutics faced a net loss in Q3 2024 but maintained strong cash reserves for operations into Q4 2025.
Positive results from SER-155 and the VOWST sale present opportunities for growth and addressing bacterial infections in patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will present a corporate overview at two upcoming investor conferences: Jefferies Virtual Healthcare Conference at 2:30 p.m. ET on Tuesday, June 1, 2021 Goldman Sachs 42nd Annual Global Healthcare Conference at 11:20 a.m. ET on Tuesday, June 8, 2021 An audio webcast of each presentation will be available under the “Investors and News” section of

Seres Therapeutics to Present at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI). The data presented today in a poster of distinction at Digestive Disease Week® 2021 demonstrated that SER-109 significantly reduced recurrence rates compared to placebo over 24

Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that David Arkowitz will join as Executive Vice President, Chief Financial Officer (CFO) and Head of Business Development, effective June 1, 2021. Mr. Arkowitz will report directly to Eric Shaff, President and Chief Executive Officer of Seres. “I am excited to welcome David to the Seres leadership team. He is a key addition as we continue to lead the development of a potentially new class of transformativ

Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the latest research from its early stage clinical development programs in two presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from June 4-8, 2021. In an oral presentation, Seres will share data from its collaboration with the University of Cologne (Köln, Germany) assessing the associat

Seres Therapeutics to Present Clinical Research on the Microbiome's Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET. A live audio webcast of the panel will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days. About Seres Therapeu

Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present recent research findings from its microbiome drug development portfolio at Digestive Disease Week® (DDW), which is taking place virtually from May 21-23, 2021. With two oral presentations and two posters of distinction, Seres will demonstrate the potential of microbiome-based therapies for patients with serious diseases like recurrent Clostr

Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2021 Results - Earnings Call Transcript

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -18.18% and 7.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q1 Loss, Tops Revenue Estimates

Shares of Seres Therapeutics (NASDAQ:MCRB) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 39.29% year over year to ($0.39), which missed the estimate of ($0.31).

Seres Therapeutics: Q1 Earnings Insights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today reported first quarter 2021 financial results and provided business updates. “We continue to make steady progress across our broad microbiome pipeline and we look forward to an eventful remainder of the year with important clinical mileston

Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2021 at 8:30 a.m. ET to discuss first quarter 2021 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 9967338. To join the live webcast, please visit the

Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021. The pre-recorded presentation will be made available under the “Investors and Media” section of Seres' website on Thursday, April 22, 2021 at 8:00 a.m. ET and will be archived for

Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit

Fecal microbiota transplantation has succeeded in various randomized ulcerative colitis trials.

Seres Therapeutics' SER-287 Is Likely To Succeed In Its Phase 2b Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, announced that managment will present a corporate overview at the 31st Annual Oppenheimer Healthcare Conference on Tuesday, March 16 at 9:20 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived

Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference

Seres Therapeutics Inc (NASDAQ: MCRB) and its study partners have voluntarily discontinued further enrollment in the Phase 1 study evaluating SER-401 in metastatic melanoma. The company cited challenges related to the pandemic.

Seres Stops Enrollment In Melanoma Study, Deprioritizes Further Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that the Company, in collaboration with study partners, The Parker Institute for Cancer Immunotherapy (PICI) and The University of Texas MD Anderson Cancer Center, has voluntarily discontinued further enrollment in the Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) study evaluating the safety and drug activity of SER-401 or fecal microbiota transplant (FMT) in comb

Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma

Boeing

Cisco Systems

Nikola

Oracle

Niu Technologies - ADR

PetMed Express

Quantum Corporation

With the trading day about halfway over, the broad markets pushed lower after a decent start to the day.

Boeing, Cisco, Nikola, Oracle and More Friday Afternoon Analyst Calls

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2020 Results - Earnings Call Transcript

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 30.77% and 99.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2020 financial results and provided business updates. “Seres continues to make progress executing against our top corporate priorities. We are enrolling our open label study to support a Biologics License Application (BLA) for SER-109, a potential first-ever FDA approved microbiome therapeutic. We have also advanced our clinical pipe

Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that the Company has achieved target enrollment of the Phase 2b ECO-RESET clinical study of SER-287 in patients with mild-to-moderate ulcerative colitis (UC) in both the U.S. and Canada. SER-287, Seres' second microbiome therapeutic to reach late-stage clinical trials following a successful Phase 3 readout for SER-109, could represent a new therapeutic paradigm for UC by targeting underlying biological dr

Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis

Axcella Health Inc

Codiak Biosciences

Denali Therapeutics

Evelo Biosciences Inc

Foghorn Therapeutics

Kaleido Biosciences Inc

Moderna

Rubius Therapeutics Inc

Sana Biotechnology

Sigilon Therapeutics

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The round included contributions from funds...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today announced that management will host a conference call and live audio webcast on March 2, 2021 at 8:30 a.m. ET to discuss fourth quarter and full year 2020 results and provide a general business update. To access the conference call

Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Seres Therapeutics (MCRB) Q4 Earnings Expected to Decline

CAMBRIDGE, Mass.--(BUSINESS WIRE)--New data from microbiome and metabolomic endpoints provide mechanistic support of Seres' positive Phase 3 results in recurrent C. difficile infection.

News for Seres Therapeutics Stock (MCRB)